Rarely is there a new medication that is really new and innovative.
Imagine a drug that deactivate methamphetamine within 2 minutes and excretes it from the body within 2 hours.
CS1103 is that drug.
Listen to this episode from the drug developers at Clear Scientific and learn about this magically innovation.
Clear Scientific
Clear Scientific was founded in Cambridge, MA, in 2019. The heart of our mission is saving lives. We are a biopharmaceutical company pioneering novel therapies for life-threatening and debilitating conditions caused by an excess of harmful substances in the body.www.clearsci.com
We are advancing a pipeline of innovative medicines in four therapeutic areas: Overdose caused by methamphetamine, fentanyl and their co-use; Accidental ADHD medication poisoning in children (Adderall and Ritalin); Reversal of neuromuscular blocking agents in anesthesia; Metabolic and neurodegenerative condition-induced CNS dysfunction.
Our pioneering work has produced a first-in-class treatment, CS-1103, for methamphetamine overdose, a critical public health crisis.
Mitch Zakin, Ph.D., Chief Scientific Officer
- 35+ years experience developing technologies for life sciences and chemical/biological defense
- Former DARPA Program Manager, Visiting Scholar Wyss Institute for Bio-Inspired Engineering at Harvard Med School; Co-Founder Soft Robotics Inc.
- , Physical Chemistry, Harvard University; BS, Chemistry CCNY
Winston Henderson, JD, General Counsel
- 25+ years experience in intellectual property/corporate law and working in technology startups from founding to exit
- Work experience Kenyon & Kenyon, Anderson Consulting, Surface Logix, Active member Board of Trustees at Boston Children’s Hospital
- JD, Duke University School of Law; BSE, Biomedical Eng & Electrical Engg.
